DGIdb - NOS3 Gene Record

NOS3 4846 Druggable Genome

Alternate Names:

4846
NITRIC OXIDE SYNTHASE 3
NOS3
ECNOS
eNOS
163729
7876
ENSG00000164867
OTTHUMG00000158343
P29474
NOS3_HUMAN
NITRIC-OXIDE SYNTHASE, ENDOTHELIAL (EC 1.14.13.39) (EC-NOS) (NOS, TYPE III) (NOSIII) (ENDOTHELIAL NOS) (ENOS) (CONSTITUTIVE NOS) (CNOS). [SOURCE:UNIPROT/SWISSPROT;ACC:P29474]
PA254
NITRIC OXIDE SYNTHASE, ENDOTHELIAL
Nitric-oxide synthase endothelial
T06046

Gene Info:

Target Class	Enzymes
Target Subclass	EC:1.14.13.39
Target Subclass	1.14.13.39
Target Main Class	Enzymes
Human Readable Name	DRUGGABLE GENOME
Uniprot Status	Swiss-Prot
Uniprot Evidence	1: Evidence at protein level
Interpro Type	Domain
Interpro Name	Oxidoreductase FAD/NAD(P)-binding
Interpro Acc	IPR001433
Interpro Short Name	OxRdtase_FAD/NAD-bd
Gene Biotype	PROTEIN_CODING

(5 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME

Publications:

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
Choi HE et al., 2011, BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells., Bioorg Med Chem Lett
Shuvalova YA et al., 2012, Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis., Mol Cell Biochem
Thorn CF et al., 2011, Doxorubicin pathways: pharmacodynamics and adverse effects., Pharmacogenet Genomics
He H et al., 2014, Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of anthracycline in Chinese patients with acute myeloid leukaemia., Clin Exp Pharmacol Physiol
Casadei Gardini A et al., 2016, eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study., Oncotarget
Venkatesan et al., 2010, Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor., J. Med. Chem.
Haruna et al., 2006, Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase., Arthritis Rheum.
Gautier et al., 2006, Dynamics of NO rebinding to the heme domain of NO synthase-like proteins from bacterial pathogens., Nitric Oxide
Akamine et al., 2006, Correction of endothelial dysfunction in diabetic female rats by tetrahydrobiopterin and chronic insulin., J. Vasc. Res.
Yang et al., 2006, L-arginine chlorination results in the formation of a nonselective nitric-oxide synthase inhibitor., J. Pharmacol. Exp. Ther.
Ishikawa et al., Identification of arginase in human placental villi., Placenta
Monti LD et al., 2015, Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: Post hoc analysis of the L-arginine trial., Metabolism
Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
Muniz JJ et al., 2013, Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction., Pharmacogenomics J
Kim KM et al., 2012, Pharmacogenetics and healthcare outcomes in patients with chronic heart failure., Eur J Clin Pharmacol
Silva PS et al., 2013, eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril., Eur J Clin Pharmacol
Moreno-Ulloa A et al., 2014, Cell membrane mediated (-)-epicatechin effects on upstream endothelial cell signaling: evidence for a surface receptor., Bioorg Med Chem Lett

ARGININE NOS3

Interaction Score: 19.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16729278 16690332 16682803 16717106 16720041 26385052

Sources:
PharmGKB
L-NAME NOS3

Interaction Score: 2.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
RONOPTERIN NOS3

Interaction Score: 2.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
SAPROPTERIN NOS3

Interaction Score: 1.41

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name Sapropterin

PMIDs:
None found

Sources:
TdgClinicalTrial TEND
SILDENAFIL NOS3

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22064666

Sources:
PharmGKB
(-)-EPICATECHIN NOS3

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24794111

Sources:
DTC
SPIRONOLACTONE NOS3

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22543981

Sources:
PharmGKB
ENALAPRIL NOS3

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22706620

Sources:
PharmGKB
EPIRUBICIN NOS3

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25545243 19671875

Sources:
PharmGKB
CLOPIDOGREL NOS3

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22890915

Sources:
PharmGKB
OXALIPLATIN NOS3

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25545243 19671875

Sources:
PharmGKB
GEDATOLISIB NOS3

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20166697

Sources:
DTC
IBUPROFEN NOS3

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
DIGOXIN NOS3

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22543981

Sources:
PharmGKB
DOXORUBICIN NOS3

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 25545243 21048526 19671875

Sources:
PharmGKB
SUNITINIB NOS3

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21963305

Sources:
DTC
CYCLOPHOSPHAMIDE NOS3

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 25545243 19671875

Sources:
PharmGKB
FLUOROURACIL NOS3

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 25545243 19671875

Sources:
PharmGKB
METHOTREXATE NOS3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 25545243 19671875

Sources:
PharmGKB
DAUNORUBICIN NOS3

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24684492

Sources:
PharmGKB
ASPIRIN NOS3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22890915

Sources:
PharmGKB
SORAFENIB NOS3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27058899

Sources:
PharmGKB

Ensembl: ENSG00000164867
- Version: 101_38
Alternate Names:

NOS3 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

RussLampel: ENSG00000164867

Version: 26-July-2011

Alternate Names:

ENSG00000164867 Ensembl Gene Id

NOS3 Display Id

NITRIC-OXIDE SYNTHASE, ENDOTHELIAL (EC 1.14.13.39) (EC-NOS) (NOS, TYPE III) (NOSIII) (ENDOTHELIAL NOS) (ENOS) (CONSTITUTIVE NOS) (CNOS). [SOURCE:UNIPROT/SWISSPROT;ACC:P29474] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TEND: P29474
- Version: 01-August-2011
Alternate Names:

ENSG00000164867 Ensembl Gene Id

P29474 Uniprot Accession

4846 Entrez Gene Id

Gene Info:

Target Subclass 1.14.13.39

Target Main Class Enzymes

Publications:
TdgClinicalTrial: P29474
- Version: January-2014
Alternate Names:

NOS3 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.14.13.39

Publications:
HopkinsGroom: P29474
- Version: 11-September-2012
Alternate Names:

NOS3_HUMAN Uniprot Id

ENSG00000164867 Ensembl Gene Id

NITRIC OXIDE SYNTHASE, ENDOTHELIAL Uniprot Protein Name

Gene Info:

Uniprot Status Swiss-Prot

Human Readable Name DRUGGABLE GENOME

Uniprot Evidence 1: Evidence at protein level

Gene Categories:

DRUGGABLE GENOME

Publications:

PharmGKB: NOS3

Version: 18-August-2020

Alternate Names:

PA254 PharmGKB ID

Gene Info:

Publications:

Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res

Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

DTC: NOS3

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Venkatesan et al., 2010, Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor., J. Med. Chem.

Choi HE et al., 2011, BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells., Bioorg Med Chem Lett

Moreno-Ulloa A et al., 2014, Cell membrane mediated (-)-epicatechin effects on upstream endothelial cell signaling: evidence for a surface receptor., Bioorg Med Chem Lett

HingoraniCasas: ENSG00000164867
- Version: 31-May-2017
Alternate Names:

ENSG00000164867 Gene Symbol

NOS3 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TTD: Nitric-oxide synthase endothelial
- Version: 2020.06.01
Alternate Names:

NOS3 TTD Gene Abbreviation

T06046 TTD Target ID

Gene Info:

Publications:

ENSG00000164867	Ensembl Gene Id
NOS3	Display Id
NITRIC-OXIDE SYNTHASE, ENDOTHELIAL (EC 1.14.13.39) (EC-NOS) (NOS, TYPE III) (NOSIII) (ENDOTHELIAL NOS) (ENOS) (CONSTITUTIVE NOS) (CNOS). [SOURCE:UNIPROT/SWISSPROT;ACC:P29474]	Description

NOS3_HUMAN	Uniprot Id
ENSG00000164867	Ensembl Gene Id
NITRIC OXIDE SYNTHASE, ENDOTHELIAL	Uniprot Protein Name

Novel drug target	Established target
Trial Name	Sapropterin

NOS3 Gene Record

NOS3 4846 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16729278 16690332 16682803 16717106 16720041 26385052

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name Sapropterin

PMIDs: None found

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22064666

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24794111

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22543981

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22706620

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25545243 19671875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22890915

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25545243 19671875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20166697

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22543981

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29938344 25545243 21048526 19671875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21963305

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29938344 25545243 19671875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29938344 25545243 19671875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
16729278 16690332 16682803 16717106 16720041 26385052

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name Sapropterin

PMIDs:
None found

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
22064666

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24794111

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22543981

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22706620

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25545243 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22890915

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25545243 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20166697

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22543981

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29938344 25545243 21048526 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21963305

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
29938344 25545243 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29938344 25545243 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29938344 25545243 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24684492

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22890915

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27058899

Sources:
PharmGKB

Alternate Names:

NOS3 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

ENSG00000164867 Ensembl Gene Id

NOS3 Display Id

NITRIC-OXIDE SYNTHASE, ENDOTHELIAL (EC 1.14.13.39) (EC-NOS) (NOS, TYPE III) (NOSIII) (ENDOTHELIAL NOS) (ENOS) (CONSTITUTIVE NOS) (CNOS). [SOURCE:UNIPROT/SWISSPROT;ACC:P29474] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

ENSG00000164867 Ensembl Gene Id

P29474 Uniprot Accession

4846 Entrez Gene Id

Gene Info:

Target Subclass 1.14.13.39

Target Main Class Enzymes

Alternate Names:

NOS3 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.14.13.39

Alternate Names:

NOS3_HUMAN Uniprot Id

ENSG00000164867 Ensembl Gene Id

NITRIC OXIDE SYNTHASE, ENDOTHELIAL Uniprot Protein Name

Gene Info:

Uniprot Status Swiss-Prot

Human Readable Name DRUGGABLE GENOME

Uniprot Evidence 1: Evidence at protein level

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

PA254 PharmGKB ID